U.S. markets open in 9 hours 17 minutes
  • S&P Futures

    4,109.75
    -13.25 (-0.32%)
     
  • Dow Futures

    33,899.00
    -97.00 (-0.29%)
     
  • Nasdaq Futures

    13,164.75
    -47.25 (-0.36%)
     
  • Russell 2000 Futures

    2,201.30
    -6.60 (-0.30%)
     
  • Crude Oil

    64.80
    -0.69 (-1.05%)
     
  • Gold

    1,869.60
    +1.60 (+0.09%)
     
  • Silver

    28.15
    -0.19 (-0.66%)
     
  • EUR/USD

    1.2237
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.6420
    +0.0020 (+0.12%)
     
  • Vix

    21.34
    +1.62 (+8.22%)
     
  • GBP/USD

    1.4191
    +0.0003 (+0.02%)
     
  • USD/JPY

    108.9070
    +0.0170 (+0.02%)
     
  • BTC-USD

    40,531.94
    -4,723.49 (-10.44%)
     
  • CMC Crypto 200

    1,118.76
    -134.39 (-10.72%)
     
  • FTSE 100

    7,034.24
    +1.39 (+0.02%)
     
  • Nikkei 225

    28,009.32
    -397.52 (-1.40%)
     

Is Mediclinic International plc (LON:MDC) Popular Amongst Institutions?

Simply Wall St
·5 min read

Every investor in Mediclinic International plc (LON:MDC) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership.

Mediclinic International has a market capitalization of UK£2.3b, so it's too big to fly under the radar. We'd expect to see both institutions and retail investors owning a portion of the company. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Let's delve deeper into each type of owner, to discover more about Mediclinic International.

Check out our latest analysis for Mediclinic International

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Mediclinic International?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Mediclinic International already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Mediclinic International's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Mediclinic International. Remgro Limited is currently the largest shareholder, with 35% of shares outstanding. Public Investment Corporation Limited is the second largest shareholder owning 8.6% of common stock, and Genesis Asset Managers, LLP holds about 5.2% of the company stock.

To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Mediclinic International

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that Mediclinic International plc insiders own under 1% of the company. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. Keep in mind that it's a big company, and the insiders own UK£2.4m worth of shares. The absolute value might be more important than the proportional share. Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

General Public Ownership

The general public holds a 23% stake in Mediclinic International. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

Private equity firms hold a 35% stake in Mediclinic International. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Mediclinic International better, we need to consider many other factors. For example, we've discovered 1 warning sign for Mediclinic International that you should be aware of before investing here.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.